In a setback to Gilead Sciences (GILD) (GILD), Malaysia will follow through on plans to issue a license to generic companies to make a version of the pricey Sovaldi hepatitis C pill. In doing so, Malaysia becomes the first country to take such a step amid growing global pushback over the cost of the groundbreaking medicine.

Patient advocates hailed the move as a significant step in widening access to a drug that has revolutionized treatment, but strained governments that are coping with high rates of infection. An estimated 500,000 people, or 2.5 per cent of the Malaysian population, are estimated to be living with the chronic liver disease, according to the Malaysian AIDS Council.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy